Form 4: Bio-Techne CEO Kim Kelderman Executes Stock Option Exercise

CEO Kim Kelderman exercised 36,500 stock options and withheld 32,088 shares to cover tax obligations.

Summary

• CEO Kim Kelderman exercised 36,500 stock options at an exercise price of $47.60.
• Following the exercise, 32,088 shares were withheld by the company to satisfy tax withholding requirements at a price of $58.66 per share.
• The net result of the transaction was an increase in the CEO's direct beneficial ownership to 53,077 shares of common stock.
• The transaction occurred on April 14, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative exercise of executive compensation rather than a signal of market sentiment or strategic shift.

Positives

• The CEO maintains a significant equity stake in the company, aligning interests with shareholders.
• The transaction reflects the exercise of long-term incentive compensation rather than a discretionary open-market sale.

Negatives

• The transaction resulted in a net increase of only 4,412 shares, as the majority of the exercised options were utilized to cover tax liabilities.

Risks

• Future share price volatility could impact the value of the remaining unvested performance-based equity awards.
• Achievement of performance goals for outstanding restricted stock units and performance options remains subject to future company performance.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing exclusively on the reporting of executive equity transactions.

Management Comments

• No narrative comments were provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that executive equity exercises are standard corporate governance events. This transaction is consistent with typical executive compensation structures in the life sciences sector, where equity-based incentives are heavily utilized to retain leadership.

Comparison to Industry Standards

• The use of 'sell-to-cover' transactions to satisfy tax obligations is a standard practice among C-suite executives in S&P 500 and mid-cap companies.
• The retention of a significant portion of equity post-exercise is viewed favorably compared to executives who liquidate entire tranches of vested options.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine exercise of existing compensation plans.

Next Steps

• Future vesting of performance-based restricted stock units and options on scheduled dates through 2035.

Key Dates

Keywords

Bio-Techne, TECH, Insider Trading, Form 4, Executive Compensation, Stock Options